Troglitazone |
10–75 μM |
|
male CD-1 mice |
isolated liver mitochondria |
Mitochondrial swelling as the indicator of mitochondrial permeability transition (MPT) was estimated from the decrease in absorbance at 540 nm. |
induce |
Positive |
|
331 |
Ciglitazone |
10–75 μM |
|
male CD-1 mice |
isolated liver mitochondria |
Mitochondrial swelling as the indicator of mitochondrial permeability transition (MPT) was estimated from the decrease in absorbance at 540 nm. |
induce |
Positive |
|
331 |
Cyclosporin A |
|
|
|
|
|
inhibit |
Positive |
|
248 |
Troglitazone |
10 µM |
6hr |
ZDF fa/fa rat vs ZDF lean rat |
hepatocytes |
Co2+-calcein assays; MPT pore opening was determined by measuring intensity of calcein fluorescence in the mitochondria quenched by cobalt and normalizing cell number of hoechst33342. |
induce |
Positive |
significantly different from ZDF lean rats (p < 0.05) |
225 |
Sulindac |
|
|
|
|
|
increase |
Positive |
|
45 |
Troglitazone |
|
|
|
|
|
increase |
Positive |
|
7 |
Chlorpromazine |
>100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Affect |
Positive |
MEC |
306 |
Thioridazine |
|
|
|
|
|
increase |
Positive |
|
49 |
JW47 |
10nM |
|
rat |
liver mitochondria |
Assess Ca2+-mediated PT pore formation by Calcium Retention Capacity Assay (Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated additions of Ca2+) |
inhibit |
Positive |
half-maximal inhibition |
324 |
Cyclosporin A |
40nM |
|
rat |
liver mitochondria |
Assess Ca2+-mediated PT pore formation by Calcium Retention Capacity Assay (Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated additions of Ca2+) |
inhibit |
Positive |
half-maximal inhibition |
324 |
Nimesulide |
|
|
|
|
|
|
Positive |
|
197 |
Berberine |
31.2 nmol/mg |
|
|
isolated rat muscle mitochondria |
evaluate mitochondrial calcium loading capacity using the fluorescence probe Calcium Green 5N |
induce |
Positive |
|
327 |
Cinnamic anilides |
|
|
|
|
swellilng assay, Rhodamine 123 (Rh123) uptake assay, Calcium retention capacity assay |
induce |
Positive |
|
290 |
chenodeoxycholic acid |
|
|
rat |
isolated liver mitochondria |
|
increase |
Positive |
|
55 |
Bupivacaine |
|
|
|
|
|
decrease |
Positive |
|
61 |
Amiodarone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
imipramine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Maprotiline |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Rotenone |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
aristolochic acid |
|
|
|
isolated kidney mitochondria |
|
increase |
Positive |
|
64 |
Tamoxifen |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Troglitazone |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
atorvastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Cerivastatin |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
fluvastatin |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
lovastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Menadione |
|
|
|
|
|
increase |
Positive |
|
35 |
Simvastatin |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Troglitazone |
10 µM |
6hr |
type 2 diabetes mellitus model rat |
primary hepatocytes or isolated mitochondria |
The loss of mitochondrial calcein and Hoechst 33342 nuclear fluorescence using a fluorescence microscope as an indicator of MPT for rat primary hepatocyte . Mitochondrial swelling as an indicator of MPT for isolated mitochondria. |
|
Positive |
|
225 |
Troglitazone |
|
|
|
|
|
increase |
Positive |
|
35 |